At a glance
ClinicalIndex Comparison RecordN/ACompleted· 51 enrolled
Drug / intervention
Atomoxetine Hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single- and Multi-Dose Study to Evaluate the Relationship Between the Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of Atomoxetine in CYP2D6 Extensive, Intermediate and Poor Metabolizers in Children With Attention Deficit/Hyperactivity Disorder
In Brief
An observational study evaluating Atomoxetine Hydrochloride for ADHD. Completed, enrolled 51 participants across 1 site.
Detailed Summary
The primary aims of this study focus on characterizing the relationship between atomoxetine exposure and clinical outcomes, as assessed by standardized measures. We will also simultaneously monitor side effect of atomoxetine, another measure of clinical outcomes, and categorize study participants on their ability to tolerate atomoxetine.
Study Details
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartDec 2017
Primary CompletionJun 2022
Study CompletionJun 2022
TodayJul 2026
First PostedMay 16, 2017
Enrollment StartDec 12, 2017
Primary CompletionJun 1, 2022
Study CompletionJun 16, 2022
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 9.1 years ago
Interventions
Atomoxetine Hydrochloridedrug
Atomoxetine dose adjusted to achieve pre-defined concentration